HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option

Anemia Clinical Trial

Official title:

Expanded Access Protocol Using HBOC-201

Clinical Trial Details — Status: Available

Administrative data

• NCT number: NCT02934282
• Other study ID #: 20160819
• Status: Available

Study information

• Verified date: November 2023
• Source: University of Miami
• Contact: Mauricio Lynn, MD
• Phone: 305-585-1178
• Email: mlynn[@]miami.edu
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. Such patients may also be referred to in this document as patients who refuse blood transfusion (PWRBT). Other patients who potentially may require HBOC-201 treatment include those with red blood cell alloantibodies for whom immunologically compatible red blood cell units cannot be found, although these patients are less common than PWRBT.

Description:

This is an open label intermediate-size patient population expanded access IND protocol. Due to our experience with management of severely anemic patients for whom blood is not an option, we anticipate encountering future patients with life-threatening anemia for whom blood is not an option. Blood is not an option in the following circumstances: - refusal of transfusion - lack of compatible red blood cells due to alloimmunity All patients with life-threatening anemia for whom blood is not an option will be treated as per the standard procedure. If those measures are not successful and the life-threatening anemia persists, then at the investigator's discretion treatment with HBOC-201 will then be considered.

Recruitment information / eligibility

• Status: Available
• Enrollment: 0
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patients = 18 years of age

2. Critically ill patients with hemoglobin < 5 g/dL (or 6-7 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits

3. Patients or their Legally Authorized Representative who are able and willing to provide informed consent

4. Blood is not an option due to:

• refusal of transfusion
• lack of compatible red blood cells

Exclusion Criteria:

1. Patients with known hypersensitivity or allergy to beef products

2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis*

3. Patients who are eligible for blood transfusions

4. Patients who are > 80 years old*

5. Pregnant

6. Lactating

• on a case by case and quality of life determination

Related Conditions & MeSH terms

• Anemia

Intervention

Drug:
• HBOC-201
Hemoglobin Based Oxygen Carrier (HBOC)

Locations

Country	Name	City	State
United States	Jackson Memorial Hospital	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Mauricio Lynn

Country where clinical trial is conducted

United States,